SCHEMBL789883

SCHEMBL789883

Nc1nc2ccc(C(=O)O)cc2cc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 5/20 0.54
RAB9A P51151 5/20 0.53
NPC1 O15118 4/20 0.53
KDM4E B2RXH2 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 3/20 0.53
GAA P10253 2/20 0.53
HPGD P15428 2/20 0.53
FGFR1 P11362 1/20 0.50
SRC P12931 1/20 0.50
NFKB1 P19838 3/20 0.49
NFKB2 Q00653 3/20 0.49
RELA Q04206 3/20 0.49
LMNA P02545 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CHEK2 O96017 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46
IP6K1 Q92551 2/20 0.44
IP6K3 Q96PC2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL790790 0.85 ALOX15 (0.50) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL807074 0.79 FGFR1 (0.57) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL17506486 0.79 ALDH1A1 (0.65) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL12474872 0.78 OPRL1 (0.48) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL789680 0.78 FGFR1 (0.55) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL31419199 0.77 GRM1 (0.46) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL8574353 0.77 KMT2A (0.74) RAB9ANPC1KDM4EALDH1A1GAA
SCHEMBL23757610 0.76 TSHR (0.47) MAP4K4RAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL23757123 0.76 TDP1 (0.53) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL790060 0.76 FGFR1 (0.54) RAB9ANPC1FGFR1SRCMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 US disclosed
WO-2021163344-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2021-08-19 WO disclosed
WO-2016022644-A1 HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-02-11 WO disclosed
WO-2012037108-A1 AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
WO-2012037108-A1 AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159510-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 MAP4K4 682/4885RAB9A 1746/4885NPC1 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.